RecruitingNCT06019975
FDG-PET in the Diagnosis of Autoimmune Encephalitis
Studying Autoimmune encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Milano Bicocca
- Principal Investigator
- Simone Beretta, MD, PhD, MDUniversity of Milano Bicocca
- Intervention
- FDG-PET(diagnostic_test)
- Enrollment
- 90 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2027
Study locations (6)
- Azienda Sanitaria Universitaria Friuli Centrale, Udine, Friuli Venezia Giulia, Italy
- IRCCS Ospedale Policlinico San Martino, Genoa, Liguria, Italy
- Fondazione IRCCS Mondino, Pavia, Lombardy, Italy
- Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Milano, Italy
- Ospedale San Paolo, Milan, Milano, Italy
- Fondazione IRCCS San Gerardo dei Tintori, Monza, Monza e Della Brianza, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06019975 on ClinicalTrials.govOther trials for Autoimmune encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07158229Long-term Impact of NMDAR Encephalitis, Level 3Hospices Civils de Lyon
- RECRUITINGNCT07477015Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune EncephalitisFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT06867991Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisThe First People's Hospital of Changzhou
- RECRUITINGNANCT06584045Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)Tongji Hospital
- RECRUITINGNCT07133113Medium-term Effects of Treatments in Autoimmune EncephalitisHospices Civils de Lyon
- RECRUITINGPHASE3NCT05503264A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisHoffmann-La Roche
- ACTIVE NOT RECRUITINGNCT07145502Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory SyndromesBiocells Medical
- RECRUITINGNANCT05198661Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis CollectionHospices Civils de Lyon